Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 July 2024 to 31 July 2024
Date: 2024-08-30
Institutions: Directorate-General for Health and Food Safety, European Commission
Subjects: EU Member State, drug surveillance, market approval, marketing standard, medicinal product, veterinary medicinal product, withdrawal from the market








C_202405166EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2024/5166


30.8.2024






Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 July 2024 to 31 July 2024
         


(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council
                (1)
or Article 5 of Regulation (EU) 2019/6 of the European Parliament and of the Council
                (2)
)


(C/2024/5166)







—



Issuing of a marketing authorisation (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted













Date of the decision


Name of the medicinal product


INN (International Non-Proprietary Name)


Holder of the marketing authorisation


Number of the entry in the Community Register


Pharmaceutical form


ATC code (Anatomical Therapeutic Chemical Code)


Date of notification




24.7.2024


Apexelsin


Paclitaxel







WhiteOak Pharmaceutical B.V.




Teleportboulevard 130, Amsterdam, 1043 EJ, Nederland






EU/1/24/1835


Powder for dispersion for infusion


L01CD01


26.7.2024




24.7.2024


Cejemly


sugemalimab







SFL Pharmaceuticals Deutschland GmbH




Marie-Curie-Strasse 8, 79539 Loerrach, Deutschland






EU/1/24/1833


Concentrate for solution for infusion


L01FF11


25.7.2024




24.7.2024


DURVEQTIX


fidanacogene elaparvovec







Pfizer Europe MA EEIG




Boulevard de la Plaine 17, 1050 Bruxelles, Belgique/ Pleinlaan 17, 1050 Brussel, België






EU/1/24/1838


Concentrate for solution for infusion


Pending


26.7.2024




24.7.2024


Kinpeygo


budesonide







STADA Arzneimittel AG




Stadastraße 2-18, 61118 Bad Vilbel, Deutschland






EU/1/22/1657


Modified-release capsule, hard


A07EA06


29.7.2024




24.7.2024


Pomalidomide Krka


pomalidomide







KRKA d d., Novo mesto




Šmarješka cesta 6, 8501 Novo mesto, Slovenija






EU/1/24/1832


Capsule, hard


L04AX06


25.7.2024




24.7.2024


Pomalidomide Zentiva


pomalidomide







Zentiva, k.s.




U Kabelovny 130, 102 37 Praha 10, Česká republika






EU/1/24/1830


Capsule, hard


L04AX06


25.7.2024




24.7.2024


Zegalogue


Dasiglucagon







Zealand Pharma A/S




Sydmarken 11, 2860 Soeborg, Danmark






EU/1/24/1829


Solution for injection


H04AA02


25.7.2024




26.7.2024


Avzivi


Bevacizumab







FGK Representative Service GmbH




Heimeranstrasse 35, 80339 München, Deutschland






EU/1/24/1834


Concentrate for solution for infusion


L01FG01


30.7.2024




26.7.2024


Dasatinib Accord Healthcare


dasatinib







Accord Healthcare S.L.U.




World Trade Center, Moll de Barcelona s/n, Edifici Est, 6a planta, 08039 Barcelona, España






EU/1/24/1839


Film-coated tablet


L01EA02


29.7.2024




26.7.2024


Pomalidomide Accord


pomalidomide







Accord Healthcare S.L.U.




World Trade Center, Moll de Barcelona, s/n, Edifici Est 6a planta, 08039 Barcelona, España






EU/1/24/1831


Capsule, hard


L04AX06


29.7.2024














—



Issuing of a marketing authorisation (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Rejected










Date of the decision


Name of the medicinal product


Holder of the marketing authorisation


Number of the entry in the Community Register


Date of notification




22.7.2024


Nezglyal







Minoryx Therapeutics S.L.




Calle Ernest Lluch 32 Tcm 3, 08302 Mataro, España






-


23.7.2024














—



Modification of a marketing authorisation (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted










Date of the decision


Name of the medicinal product


Holder of the marketing authorisation


Number of the entry in the Community Register


Date of notification




3.7.2024


Comirnaty







BioNTech Manufacturing GmbH




An der Goldgrube 12, 55131 Mainz, Deutschland






EU/1/20/1528


4.7.2024




5.7.2024


Aldara







Viatris Healthcare Limited




Damastown Industrial Park, Mulhuddart, Dublin 15, Ireland






EU/1/98/080


8.7.2024




5.7.2024


Carbaglu







Recordati Rare Diseases




Immeuble Le Wilson, 70 avenue du Général de Gaulle, 92800 Puteaux, France






EU/1/02/246


10.7.2024




5.7.2024


Cosentyx







Novartis Europharm Limited




Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland






EU/1/14/980


8.7.2024




5.7.2024


Darunavir Viatris







Viatris Limited




Damastown Industrial Park, Mulhuddart, Dublin 15, DUBLIN, Ireland






EU/1/16/1140


8.7.2024




5.7.2024


Inrebic







Bristol-Myers Squibb Pharma EEIG




Plaza 254, Blanchardstown Corporate Park 2, D15 T867, Dublin 15, Ireland






EU/1/20/1514


8.7.2024




5.7.2024


Iressa







AstraZeneca AB




151 85 Södertälje, Sverige






EU/1/09/526


8.7.2024




5.7.2024


Jylamvo







Oresund Pharma ApS




Orient Plads 1, 2150 Nordhavn, Hovedstaden, Danmark






EU/1/17/1172


8.7.2024




5.7.2024


Lonquex







Teva B.V.




Swensweg 5, 2031 GA Haarlem, Nederland






EU/1/13/856


8.7.2024




5.7.2024


Neulasta







Amgen Europe B.V.




Minervum 7061, 4817 ZK Breda, Nederland






EU/1/02/227


8.7.2024




5.7.2024


NovoMix







Novo Nordisk A/S




Novo Allé, 2880 Bagsvaerd, Danmark






EU/1/00/142


8.7.2024




5.7.2024


Pergoveris







Merck Europe B.V.




Gustav Mahlerplein 102, 1082 MA Amsterdam, Nederland






EU/1/07/396


8.7.2024




5.7.2024


Ristaben







Merck Sharp & Dohme B.V.




Waarderweg 39, 2031 BN Haarlem, Nederland






EU/1/10/621


9.7.2024




5.7.2024


Ronapreve







Roche Registration GmbH




Emil-Barell-Strasse 1, 79639 Grenzach-Wyhlen, Deutschland






EU/1/21/1601


8.7.2024




5.7.2024


Saxenda







Novo Nordisk A/S




Novo Allé, 2880 Bagsvaerd, Danmark






EU/1/15/992


8.7.2024




5.7.2024


Sibnayal







ADVICENNE




262, rue du Faubourg Saint Honoré 75008 Paris, France






EU/1/20/1517


8.7.2024




5.7.2024


Temozolomide Accord







Accord Healthcare S.L.U.




World Trade Center, Moll de Barcelona, s/n, Edifici Est 6a planta, 08039 Barcelona, España






EU/1/10/615


8.7.2024




5.7.2024


Tigecycline Accord







Accord Healthcare S.L.U.




World Trade Center, Moll de Barcelona, s/n, Edifici Est 6a planta, 08039 Barcelona, España






EU/1/19/1394


8.7.2024




5.7.2024


TUKYSA







Pfizer Europe MA EEIG




Boulevard de la Plaine 17, 1050 Bruxelles, Belgique/ Pleinlaan 17, 1050 Brussel, België






EU/1/20/1526


11.7.2024




5.7.2024


ZTALMY







Marinus Pharmaceuticals Emerald Limited




10 Earlsfort Terrace, Dublin 2, D02 T380, Ireland






EU/1/23/1743


10.7.2024




8.7.2024


Sugammadex Amomed







AOP Orphan Pharmaceuticals GmbH




Leopold-Ungar-Platz 2, 1190 Wien, Österreich






EU/1/22/1708


11.7.2024




8.7.2024


Tevimbra







BeiGene Ireland Limited




10 Earlsfort Terrace, Dublin 2, D02 T380, Ireland






EU/1/23/1758


9.7.2024




8.7.2024


Victoza







Novo Nordisk A/S




Novo Allé, 2880 Bagsvaerd, Danmark






EU/1/09/529


9.7.2024




12.7.2024


Ocaliva







ADVANZ PHARMA Limited




Suite 17, Northwood House, Northwood Avenue, Santry, Dublin 9, Ireland






EU/1/16/1139


15.7.2024




12.7.2024


Ristfor







Merck Sharp & Dohme B.V.




Waarderweg 39, 2031 BN Haarlem, Nederland






EU/1/10/620


16.7.2024




12.7.2024


Soliris







Alexion Europe SAS




103-105 rue Anatole France, 92300 Levallois-Perret, France






EU/1/07/393


15.7.2024




17.7.2024


Accofil







Accord Healthcare S.L.U.




World Trade Center, Moll de Barcelona, s/n, Edifici Est 6a planta, 08039 Barcelona, España






EU/1/14/946


18.7.2024




17.7.2024


Fluenz







AstraZeneca AB




151 85 Södertälje, Sverige






EU/1/24/1816


18.7.2024




17.7.2024


Galvus







Novartis Europharm Limited




Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland






EU/1/07/414


18.7.2024




17.7.2024


GAVRETO







Blueprint Medicines (Netherlands) B.V.




Gustav Mahlerplein 2, 1082 MA Amsterdam, Nederland






EU/1/21/1555


18.7.2024




17.7.2024


Minjuvi







Incyte Biosciences Distribution B.V.




Paasheuvelweg 25, 1105 BP Amsterdam, Nederland






EU/1/21/1570


18.7.2024




17.7.2024


Rekovelle







Ferring Pharmaceuticals A/S




Amager Strandvej 405, 2770 Kastrup, Danmark






EU/1/16/1150


23.7.2024




17.7.2024


Ritonavir Viatris







Viatris Limited




Damastown Industrial Park, Mulhuddart, Dublin 15, DUBLIN, Ireland






EU/1/17/1242


18.7.2024




17.7.2024


Tepkinly







AbbVie Deutschland GmbH & Co. KG




Knollstrasse, 67061 Ludwigshafen, Deutschland






EU/1/23/1759


18.7.2024




18.7.2024


Levetiracetam SUN







Sun Pharmaceutical Industries Europe BV




Polarisavenue 87, 2132 JH Hoofddorp, Nederland






EU/1/11/741


25.7.2024




18.7.2024


Retacrit







Pfizer Europe MA EEIG




Boulevard de la Plaine 17, 1050 Bruxelles, Belgique/ Pleinlaan 17, 1050 Brussel, België






EU/1/07/431


18.7.2024




19.7.2024


Hyrimoz







Sandoz GmbH




Biochemiestrasse 10, 6250 Kundl, Österreich






EU/1/18/1286


22.7.2024




19.7.2024


Piqray







Novartis Europharm Limited




Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland






EU/1/20/1455


22.7.2024




19.7.2024


Pregabalin Viatris







Viatris Limited




Damastown Industrial Park, Mulhuddart, Dublin 15, DUBLIN, Ireland






EU/1/15/997


24.7.2024




19.7.2024


Scemblix







Novartis Europharm Limited




Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland






EU/1/22/1670


22.7.2024




19.7.2024


Votrient







Novartis Europharm Limited




Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland






EU/1/10/628


22.7.2024




22.7.2024


Avonex







Biogen Netherlands B.V.




Prins Mauritslaan 13, 1171 LP Badhoevedorp, Nederland






EU/1/97/033


23.7.2024




22.7.2024


Byfavo







PAION Pharma GmbH




Heussstraße 25, 52078 Aachen, Deutschland






EU/1/20/1505


25.7.2024




22.7.2024


Deferasirox Mylan







Mylan Pharmaceuticals Limited




Damastown Industrial Park, Mulhuddart, Dublin 15, DUBLIN, Ireland






EU/1/19/1386


23.7.2024




22.7.2024


Norvir







AbbVie Deutschland GmbH & Co. KG




Knollstrasse, 67061 Ludwigshafen, Deutschland






EU/1/96/016


23.7.2024




22.7.2024


Slenyto







RAD Neurim Pharmaceuticals EEC SARL




4 rue de Marivaux, 75002 Paris, France






EU/1/18/1318


25.7.2024




22.7.2024


Teriflunomide Mylan







Mylan Pharmaceuticals Limited




Damastown Industrial Park, Mulhuddart, Dublin 15, DUBLIN, Ireland






EU/1/22/1698


23.7.2024




22.7.2024


VITRAKVI







Bayer AG




D-51368 Leverkusen, Deutschland






EU/1/19/1385


23.7.2024




23.7.2024


Prometax







Almirall, S.A.




Ronda General Mitre, 151, 08022 Barcelona, España






EU/1/98/092


25.7.2024




24.7.2024


AUBAGIO







Sanofi Winthrop Industrie




82 avenue Raspail, 94250 Gentilly, France






EU/1/13/838


25.7.2024




24.7.2024


Buvidal







Camurus AB




Ideon Science Park, 223 70 Lund, Sverige






EU/1/18/1336


25.7.2024




24.7.2024


Bydureon







AstraZeneca AB




151 85 Södertälje, Sverige






EU/1/11/696


25.7.2024




24.7.2024


Bylvay







Ipsen Pharma




65 quai Georges Gorse, 92100 Boulogne-Billancourt, France






EU/1/21/1566


29.7.2024




24.7.2024


Caprelsa







Sanofi B.V.




Paasheuvelweg 25, 1105 BP Amsterdam, Nederland






EU/1/11/749


25.7.2024




24.7.2024


Fluad Tetra







Seqirus Netherlands B.V.




Paasheuvelweg 28, 1105 BJ Amsterdam, Nederland






EU/1/20/1433


25.7.2024




24.7.2024


Flucelvax Tetra







Seqirus Netherlands B.V.




Paasheuvelweg 28, 1105 BJ Amsterdam, Nederland






EU/1/18/1326


25.7.2024




24.7.2024


Idefirix







Hansa Biopharma AB




P.O. Box 785, 220 07 Lund, Sverige






EU/1/20/1471


25.7.2024




24.7.2024


Ilumetri







Almirall, S.A.




Ronda General Mitre, 151, 08022 Barcelona, España






EU/1/18/1323


29.7.2024




24.7.2024


JCOVDEN







Janssen-Cilag International NV




Turnhoutseweg 30, 2340 Beerse, België






EU/1/20/1525


25.7.2024




24.7.2024


Kaletra







AbbVie Deutschland GmbH & Co. KG




Knollstrasse, 67061 Ludwigshafen, Deutschland






EU/1/01/172


25.7.2024




24.7.2024


Leflunomide medac







medac Gesellschaft für klinische Spezialpräparate mbH




Theaterstraße 6, 22880 Wedel, Deutschland






EU/1/10/637


25.7.2024




24.7.2024


Leflunomide Zentiva







Zentiva k.s.




U kabelovny 130, 102 37 Praha 10, Česká republika






EU/1/09/604


29.7.2024




24.7.2024


Mvabea







Janssen-Cilag International NV




Turnhoutseweg 30, 2340 Beerse, België






EU/1/20/1445


25.7.2024




24.7.2024


Nexavar







Bayer AG




D-51368 Leverkusen, Deutschland






EU/1/06/342


25.7.2024




24.7.2024


Pregabalin Viatris







Viatris Limited




Damastown Industrial Park, Mulhuddart, Dublin 15, DUBLIN, Ireland






EU/1/15/997


25.7.2024




24.7.2024


Pyzchiva







Samsung Bioepis NL B.V.




Olof Palmestraat 10, 2616 LR Delft, Nederland






EU/1/24/1801


30.7.2024




24.7.2024


Skyrizi







AbbVie Deutschland GmbH & Co. KG




Knollstrasse, 67061 Ludwigshafen, Deutschland






EU/1/19/1361


25.7.2024




24.7.2024


Suboxone







Indivior Europe Limited




27 Windsor Place, Dublin 2, D02 DK44, Ireland






EU/1/06/359


25.7.2024




24.7.2024


TUKYSA







Pfizer Europe MA EEIG




Boulevard de la Plaine 17, 1050 Bruxelles, Belgique/ Pleinlaan 17, 1050 Brussel, België






EU/1/20/1526


30.7.2024




26.7.2024


Artesunate Amivas







Amivas Ireland Ltd




Suite 5, Second Floor, Station House, Railway Square, Waterford, Ireland






EU/1/21/1582


31.7.2024




26.7.2024


AYVAKYT







Blueprint Medicines (Netherlands) B.V.




Gustav Mahlerplein 2, 1082 MA Amsterdam, Nederland






EU/1/20/1473


29.7.2024




26.7.2024


Efficib







Merck Sharp & Dohme B.V.




Waarderweg 39, 2031 BN Haarlem, Nederland






EU/1/08/457


29.7.2024




26.7.2024


Eliquis







Bristol-Myers Squibb/Pfizer EEIG




Plaza 254, Blanchardstown Corporate Park 2, Dublin 15, D15 T867, Ireland






EU/1/11/691


29.7.2024




26.7.2024


Epidyolex







Jazz Pharmaceuticals Ireland Ltd




5th Floor, Waterloo Exchange, Waterloo Road, Dublin D04 E5W7, Ireland






EU/1/19/1389


30.7.2024




26.7.2024


Fareston







Orion Corporation




Orionintie 1, 02200 Espoo, Suomi






EU/1/96/004


29.7.2024




26.7.2024


Imcivree







Rhythm Pharmaceuticals Netherlands B.V.




Radarweg 29, 1043 NX Amsterdam, Nederland






EU/1/21/1564


29.7.2024




26.7.2024


Imfinzi







AstraZeneca AB




151 85 Södertälje, Sverige






EU/1/18/1322


29.7.2024




26.7.2024


Janumet







Merck Sharp & Dohme B.V.




Waarderweg 39, 2031 BN Haarlem, Nederland






EU/1/08/455


29.7.2024




26.7.2024


Orladeyo







Biocryst Ireland Limited




Block 4, Harcourt Centre, Harcourt Road, Dublin 2, D02 HW77, Ireland






EU/1/21/1544


29.7.2024




26.7.2024


Quinsair







Chiesi Farmaceutici S.p.A.




Via Palermo 26/A, 43122 Parma, Italia






EU/1/14/973


31.7.2024




26.7.2024


Teriflunomide Accord







Accord Healthcare S.L.U.




World Trade Center, Moll de Barcelona s/n, Edifici Est, 6a planta, 08039 Barcelona, España






EU/1/22/1693


29.7.2024




26.7.2024


Vabysmo







Roche Registration GmbH




Emil-Barell-Strasse 1, 79639 Grenzach-Wyhlen, Deutschland






EU/1/22/1683


29.7.2024




26.7.2024


Velmetia







Merck Sharp & Dohme B.V.




Waarderweg 39, 2031 BN Haarlem, Nederland






EU/1/08/456


29.7.2024




26.7.2024


Vumerity







Biogen Netherlands B.V.




Prins Mauritslaan 13, 1171 LP Badhoevedorp, Nederland






EU/1/21/1585


31.7.2024




26.7.2024


Zubsolv







Accord Healthcare S.L.U.




World Trade Center, Moll de Barcelona s/n, Edifici Est, 6a planta, 08039 Barcelona, España






EU/1/17/1233


29.7.2024




29.7.2024


Atazanavir Viatris







Viatris Limited




Damastown Industrial Park, Mulhuddart, Dublin 15, DUBLIN, Ireland






EU/1/16/1091


30.7.2024




29.7.2024


Jalra







Novartis Europharm Limited




Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland






EU/1/08/485


1.8.2024




29.7.2024


Lopinavir/Ritonavir Viatris







Viatris Limited




Damastown Industrial Park, Mulhuddart, Dublin 15, DUBLIN, Ireland






EU/1/15/1067


30.7.2024




29.7.2024


Myalepta







Chiesi Farmaceutici S.p.A.




Via Palermo 26/A, 43122 Parma, Italia






EU/1/18/1276


30.7.2024




29.7.2024


Rasagiline Viatris







Viatris Limited




Damastown Industrial Park, Mulhuddart, Dublin 15, DUBLIN, Ireland






EU/1/16/1090


30.7.2024




29.7.2024


Xiliarx







Novartis Europharm Limited




Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland






EU/1/08/486


1.8.2024














—



Withdrawal of a marketing authorisation (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)









Date of the decision


Name of the medicinal product


Holder of the marketing authorisation


Number of the entry in the Community Register


Date of notification




5.7.2024


Evicel







Omrix Biopharmaceuticals N.V.




Leonardo Da Vincilaan 15, 1831 Diegem, België






EU/1/08/473


8.7.2024




5.7.2024


Tizveni







BeiGene Ireland Limited




10 Earlsfort Terrace, Dublin 2, D02 T380, Ireland






EU/1/24/1797


10.7.2024




18.7.2024


Esmya







Gedeon Richter Plc.




Gyömrői út 19-21, 1103 Budapest, Magyarország






EU/1/12/750


18.7.2024




26.7.2024


JCOVDEN







Janssen-Cilag International NV




Turnhoutseweg 30, 2340 Beerse, België






EU/1/20/1525


29.7.2024














—



Issuing of a marketing authorisation (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council; Article 5 of Regulation (EU) 2019/6 of the European Parliament and of the Council): Accepted













Date of the decision


Name of the medicinal product


INN (International Non-Proprietary Name)


Holder of the marketing authorisation


Number of the entry in the Community Register


Pharmaceutical form


ATC code (Anatomical Therapeutic Chemical Code)


Date of notification




5.7.2024


Nobilis Multriva RT+IBm+ND+Gm+REOm


Avian metapneumovirus, avian infectious bronchitis virus, Newcastle disease virus, avian infectious bursal disease virus and avian reovirus vaccine (inactivated)







Intervet International B.V.




Wim de Körverstraat 35, 5831 AN Boxmeer, Nederland






EU/2/24/317


Emulsion for injection


QI01AA26


8.7.2024




17.7.2024


Nobilis Multriva RT+IBm+ND+EDS


Avian metapneumovirus, infectious bronchitis virus, Newcastle disease virus and egg drop syndrome virus vaccine, inactivated.







Intervet International B.V.




Wim de Körverstraat 35, 5831 AN Boxmeer, Nederland






EU/2/24/316


Emulsion for injection


Pending


18.7.2024














—



Modification of a marketing authorisation (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council; Article 5 of Regulation (EU) 2019/6 of the European Parliament and of the Council): Accepted










Date of the decision


Name of the medicinal product


Holder of the marketing authorisation


Number of the entry in the Community Register


Date of notification




5.7.2024


Felpreva







Vetoquinol S.A.




Magny-Vernois, 70200 Lure, France






EU/2/21/277


8.7.2024




5.7.2024


Forceris







Ceva Santé Animale




10 avenue de La Ballastière, 33500 Libourne, France






EU/2/19/235


8.7.2024




5.7.2024


Isemid







Ceva Santé Animale




10 avenue de La Ballastière, 33500 Libourne, France






EU/2/18/232


9.7.2024




5.7.2024


Nobivac LoVo L4







Intervet International B.V.




Wim de Körverstraat 35, 5831 AN Boxmeer, Nederland






EU/2/23/304


8.7.2024




5.7.2024


Vectra 3D







Ceva Santé Animale




10 avenue de La Ballastière, 33500 Libourne, France






EU/2/13/156


8.7.2024




5.7.2024


Vectra Felis







Ceva Santé Animale




10 avenue de La Ballastière, 33500 Libourne, France






EU/2/14/165


8.7.2024




5.7.2024


Virbagen Omega







VIRBAC




1ère Avenue - 2065m – L.I.D., 06516 CARROS, France






EU/2/01/030


8.7.2024




8.7.2024


Circovac







CEVA-Phylaxia Co. Ltd




Szállás u. 5, 1107 Budapest, Magyarország






EU/2/07/075


10.7.2024




8.7.2024


HorStem







EquiCord S.L




103-D Loeches, Polígono. Industrial Ventorro del Cano, Alcorcón, 28925 Madrid, España.






EU/2/18/226


11.7.2024




11.7.2024


BLUEVAC BTV







CZ Vaccines S.A.U.




A Relva s/n – Torneiros 36410 O Porriño Pontevedra, España






EU/2/11/122


12.7.2024




11.7.2024


Porcilis AR-T DF







Intervet International B.V.




Wim de Körverstraat 35, 5831 AN Boxmeer, Nederland






EU/2/00/026


12.7.2024




Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:





European Medicines Agency




Domenico Scarlattilaan 6




1083 HS Amsterdam




NETHERLANDS










(1)  
            OJ L 136, 30.4.2004, p. 1, ELI: 
https://data.europa.eu/eli/reg/2004/726/oj
.

(2)  
            OJ L 4, 7.1.2019, p. 43, ELI: 
https://data.europa.eu/eli/reg/2019/6/oj
.


ELI: http://data.europa.eu/eli/C/2024/5166/oj
ISSN 1977-091X (electronic edition)